NAMS241220P10000
- 0.37
- 0.000.00%
NewAmsterdam Pharma Newsroom
Analysts Conflicted on These Healthcare Names: NewAmsterdam Pharma Company (NAMS) and Roche Holding AG (OtherRHHVF)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
NewAmsterdam Pharma Analyst Ratings
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Piper Sandler
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Clinical Trials and Innovative Lipid-Lowering Therapies
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
NewAmsterdam Pharma Analyst Ratings
NewAmsterdam Pharma's Strategic Advancements: Phase 3 Trials and Buy Rating Insight
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $36